No insider purchase over the last 90 days. The latest, by Jakob Riis, was filed 06 Feb 2026.
Analysts rate H. Lundbeck A/S Buy (bullish), based on 12 analysts. Average price target: DKK 47.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 86 declarations
Of 86 filings published from August 22, 2006 to September 17, 2026, H. Lundbeck A/S, a Danish health care company listed in Copenhagen (market capitalisation of DKK 42.1 billion), has 40 purchases (14 with an amount, EUR 1,523,712, median EUR 66,777) and 25 sales (16 with an amount, EUR 20,548,614, median EUR 660,458). Sales weigh more in value, purchases in number: 62% purchases among open-market trades.
The three largest sales date from 2017: Anders Gersel Pedersen, EUR 7,817,552 on August 23, 2017 and EUR 3,792,351 on November 21, 2017, and Kåre Schultz, EUR 2,327,712 on May 29, 2017. The largest purchase, EUR 487,783, is by Lars Holmqvist on November 7, 2016, ahead of Jakob Riis (EUR 268,277, May 12, 2023) and Deborah Dunsire (EUR 133,726, March 4, 2021).
Anders Gersel Pedersen has 9 filings, 5 of them sales, Lars Bang 8, Ulf Wiinberg 6 of which 5 purchases. Thirty-nine filers appear in the record and hold 0.1% of the capital. The annual pace runs from 1 filing (2014) to 11 (2017). Five fall in the last twelve months, one purchase and 2 sales. The publication delay is a median of 0 days.